SciBX: Science-Business eXchange Contents: March 28 2013, Volume 6 / Issue 12

TABLE OF CONTENTS March 28 2013, Volume 6 / Issue 12 Analysis Cover Story Targets and Mechanisms Tools The Distillery: Therapeutics Cancer Dermatology Endocrine/metabolic disease Hematology Infectious disease Musculoskeletal disease Other Transplantation The Distillery: Techniques Assays and screens Disease models Drug platforms Advertisement BioPharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The December 2012 issue of BioPharma Dealmakers showcases companies with partnering opportunities and contains a special feature on China's emerging biotech industry. This week, find out about how you can collaborate with BioBAY. Nature Publishing Group and Relay Technology Management present: The Epigenetics Target Explorer  Click here to access this free online tool and the accompanying article in Nature Reviews Drug Discovery.  SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Bromodomains on the brain Joanne Kotz doi:10.1038/scibx.2013.277 A Dana-Farber–led team has found that MYCN amplification provides a marker for sensitivity to BET bromodomain inhibition in neuroblastomas. GSK is using the marker as one criterion to select patients for a Phase I trial of its BET bromodomain inhibitor in cancer. Full Text | PDF Targets and Mechanisms Top SMAD men Tim Fulmer doi:10.1038/scibx.2013.278 University of Colorado researchers have shown that topical application of the signaling protein Smad7 can treat and prevent oral mucositis in mice. The team will now test the compound in mice with cancer-associated mucositis—a condition with limited therapeutic options. Full Text | PDF mAb attack on WT1 Kai-Jye Lou doi:10.1038/scibx.2013.279 Researchers at Eureka Therapeutics and Memorial Sloan-Kettering have targeted Wilms tumor 1–positive cancer cells with a mAb against peptide fragments derived from the protein that are presented on the cells' surface. The biotech hopes to have the mAb in a Phase I trial in leukemia within two years. Full Text | PDF Tools Top Awakening tumor immunity Lev Osherovich doi:10.1038/scibx.2013.280 MD Anderson researchers have figured out why many cancer vaccines fail to elicit a robust T cell response—the cells loiter near the vaccination site instead of migrating to the tumor. The solution is switching the vaccine formulation to a different carrier. Full Text | PDF Distillery: Therapeutics Cancer Top B cell lymphoma 2 (BCL-2; BCL2); tyrosine kinase 2 (TYK2); signal transducer and activator of transcription 1 (STAT1) doi:10.1038/scibx.2013.281 Mouse and cell culture studies suggest inhibiting the TYK2-STAT1-BCL2 signaling pathway could help treat T cell ALL. Full Text | PDF Bromodomain containing 4 (BRD4); v-myc myelocytomatosis viral related oncogene neuroblastoma derived (MYCN; NMYC) doi:10.1038/scibx.2013.282 Cell profiling and mouse studies suggest inhibiting BET bromodomains could help treat neuroblastomas with MYCN amplification. Full Text | PDF Endothelial PAS domain protein 1 (EPAS1; HIF2A) doi:10.1038/scibx.2013.283 In vitro and cell culture studies identified a small molecule inhibitor of HIF2A that could help treat cancer. Full Text | PDF Unknown doi:10.1038/scibx.2013.284 In vitro and mouse studies identified fucosylation inhibitors that could help treat various diseases including cancers. Full Text | PDF Epiregulin (EREG) doi:10.1038/scibx.2013.285 In vitro and mouse studies suggest inhibiting EREG could help treat colitis-associated colorectal cancer. Full Text | PDF Human leukocyte antigen (HLA); Wilms tumor 1 (WT1) doi:10.1038/scibx.2013.286 Mouse and cell culture studies suggest a human mAb targeting the WT1-HLA complex could help treat leukemia and solid tumors. Full Text | PDF Dermatology Top Wiskott-Aldrich syndrome–like (WASL; N-WASP) doi:10.1038/scibx.2013.287 In vitro and mouse studies suggest inhibiting the interaction between mycolactone and N-WASP could help treat Buruli ulcers. Full Text | PDF Endocrine/metabolic disease Top Sirtuin 1 (SIRT1) doi:10.1038/scibx.2013.288 In vitro and mouse studies suggest inhibiting SIRT1 specifically in neurons could help treat type 2 diabetes. Full Text | PDF Sirtuin 1 (SIRT1) doi:10.1038/scibx.2013.289 In vitro studies identified a SIRT1 mutation that could be associated with type 1 diabetes. Full Text | PDF ATP-binding cassette sub-family G WHITE member 2 (ABCG2; MXR; BCRP1) doi:10.1038/scibx.2013.290 In vitro studies identified small molecule structural correctors of ABCG2 that could help treat gout. Full Text | PDF Hematology Top Prostaglandin E2 receptor EP4 subtype (prostanoid EP4 receptor; PTGER4) doi:10.1038/scibx.2013.291 In vivo studies suggest PTGER4 inhibition could help stimulate hematopoietic progenitor cell (HPC) mobilization into peripheral blood for transplantation. Full Text | PDF Infectious disease Top Not applicable doi:10.1038/scibx.2013.292 Two studies suggest reactive oxygen species (ROS) production may not be the major contributor to bactericidal activity. Full Text | PDF Musculoskeletal disease Top Proteoglycan 4 (PRG4; HAPO) doi:10.1038/scibx.2013.293 A study in mice suggests enhancing levels of PRG4 in joints could help treat OA. Full Text | PDF Other Top Mothers against decapentaplegic homolog 7 (MADH7; SMAD7) doi:10.1038/scibx.2013.294 A study in mice suggests delivering recombinant SMAD7 directly to the oral mucosa could help treat oral mucositis, which is often associated with cancer radiotherapy. Full Text | PDF Transplantation Top Delta-like 1 (DLL1); DLL4 doi:10.1038/scibx.2013.295 Mouse studies suggest mAbs against DLL1 and DLL4 could be useful for preventing GvHD. Full Text | PDF Distillery: Techniques Assays and screens Top Mutant methionyl-tRNA synthetase for protein labeling doi:10.1038/scibx.2013.296 Expression of a mutant methionyl-tRNA synthetase derived from Escherichia coli could be useful for producing modified variants of therapeutic proteins. Full Text | PDF Disease models Top Models for pathogenic mutations in vasolin containing protein (VCP) doi:10.1038/scibx.2013.297 Fruit flies and human cells with pathogenic mutations in VCP could be useful as models to study diseases associated with such mutations, such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Full Text | PDF Drug platforms Top Automated, high throughput, microfluidic SAR platform doi:10.1038/scibx.2013.298 An automated, microfluidic SAR platform could be used to rapidly optimize kinase inhibitors. Full Text | PDF Single-component, polymer optoelectronic interface to restore retinal light sensitivity doi:10.1038/scibx.2013.299 A single-component, polymer optoelectronic interface that restores retinal light sensitivity could be useful in the development of implantable devices to treat blindness. Full Text | PDF Transglutaminase (TGM)-mediated synthesis of antibody-drug conjugates (ADCs) doi:10.1038/scibx.2013.300 In vitro and rodent studies suggest conjugating chemotherapeutics to engineered glutamine residues could improve the in vivo pharmacokinetics of ADCs. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.